Lilly Enters Psychedelic Drug Race with $3.8 Billion AtaiBeckley Acquisition| Business Honor

Lilly Enters Psychedelic Drug Race with $3.8 Billion AtaiBeckley Acquisition

Bio Tech

Eli Lilly's $3.8 billion AtaiBeckley acquisition accelerates psychedelic therapy for treatment-resistant depression, strengthening its neuroscience pipeline and advancing next-generation mental health treatments globally.

Eli Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion
The agreement includes $2.8 billion upfront and $1 billion in milestone payments
Lilly gains access to BPL-003, a late-stage psychedelic nasal spray for treatment-resistant depression
Initial Phase III trial results are expected in 2029
The acquisition expands Lilly's neuroscience and mental health portfolio

In a move towards the emerging psychedelic drugs market, Eli Lilly has announced a deal to buy biotechnology firm AtaiBeckley for up to $3.8 billion. This deal marks Lilly's increased presence in the neuroscience field and the trend among pharmaceutical companies to pursue psychedelic therapy for treatment-resistant depression.

The deal involves an initial cash payment of $2.8 billion, as well as an additional $1 billion contingent payment depending on future milestones. Both the acquirer and the target expect the deal to be completed in the third quarter of 2026.

An important factor in the Eli Lilly acquisition deal is the investigational therapy, BPL-003, owned by AtaiBeckley. The BPL-003 psychedelic spray for depression is under late-stage clinical development for patients suffering from depression that cannot be treated through existing therapies. Early phase III results for BPL-003 are anticipated in early 2029.

It further aligns with Lilly’s overall strategy of diversification from its very profitable weight loss drugs through the next generation of mental health therapies. The analysts expect that the drug BPL-003 may generate between $1 billion and $2 billion in annual sales when it successfully passes clinical trials and gets approved.

The investors' enthusiasm is evidenced by the rise in the AtaiBeckley share price by over 30% after the news was released, and even other companies involved in the development of psychedelics experienced growth. According to industry analysts, increased investments by the pharmaceutical industry in psychedelic drugs can revolutionize depression therapy, and the global market of psychedelics will reach $12 billion by 2034. Business Honor observes that the acquisition highlights the pharmaceutical industry's growing focus on psychedelic therapies as a promising frontier for future mental health innovation.

Frequently Asked Questions

Eli Lilly is acquiring AtaiBeckley to strengthen its neuroscience portfolio and expand into the growing psychedelic medicine market with innovative mental health therapies.

BPL-003 is a late-stage psychedelic nasal spray for treatment-resistant depression. Business Honor notes it could provide a new option for patients who do not respond to conventional treatments.

The deal is valued at up to $3.8 billion, including $2.8 billion upfront and up to $1 billion in milestone payments, pending regulatory approval.

The acquisition helps Lilly diversify beyond weight-loss medicines while expanding its neuroscience pipeline with next-generation mental health treatments.